You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Details for Patent: 9,763,954


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,763,954 protect, and when does it expire?

Patent 9,763,954 protects APTIOM and is included in one NDA.

This patent has twenty-eight patent family members in twenty-five countries.

Summary for Patent: 9,763,954
Title:Therapeutical uses of eslicarbazepine
Abstract: New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions.
Inventor(s): Soares Da Silva; Patricio Manuel Vieira Ara (Porto, PT)
Assignee: BIAL--PORTELA & CA, S.A. (S. Mamede do Coronado, PT)
Application Number:14/134,843
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,763,954
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,763,954

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-001 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-002 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-003 Nov 8, 2013 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE ⤷  Try a Trial
Sumitomo Pharma Am APTIOM eslicarbazepine acetate TABLET;ORAL 022416-004 Nov 8, 2013 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,763,954

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0700773.5Jan 15, 2007

International Family Members for US Patent 9,763,954

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 064898 ⤷  Try a Trial
Australia 2008205712 ⤷  Try a Trial
Brazil PI0806568 ⤷  Try a Trial
Canada 2674303 ⤷  Try a Trial
China 101605571 ⤷  Try a Trial
Cyprus 1118297 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.